Identification of resistance biomarkers to anti-HER2 agents in HER2-positive metastatic gastric c...

Università degli Studi delle Campania
October 05 2017
Position Type
Full Time
Organization Type

The selection of HER2 positive metastatic gastric cancer patients candidates for anti-HER2 agents is a challenge of precision oncology. Several genomic mechanisms of resistance, leading to activation of tyrosine kinase receptors other than HER2 or downstream signaling pathways, have been suggested by preclinical studies. The aim of this study is the identificaction of genomic alterations including EGFR/MET/KRAS/PI3K/PTEN mutations and EGFR/MET/KRAS amplifications in HER2-positive mGC patients eligible for first-line treatment with anti-HER2 agents and chemotherapy

This job comes from a partnership with Science Magazine and Euraxess